Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

Gabrielle Meyers; Mehdi Hamadani; Michael Martens; Haris Ali; Hannah Choe; Peter Dawson; Andrew C. Harris; Eric van Hooren; Willem Klaassen; Eric Leifer; Margaret L. MacMillan; Ypke van Oosterhout; Lia Perez; Iskra Pusic; Phuong Vo; John E. Levine

doi:10.1038/s41409-021-01529-x

Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Hannah Choe, Peter Dawson, Andrew C. Harris, Eric van Hooren, Willem Klaassen, Eric Leifer, Margaret L. MacMillan, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Phuong Vo, John E. Levine

Pediatrics - Blood/Marrow Transplant

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	302-303
Number of pages	2
Journal	Bone marrow transplantation
Volume	57
Issue number	2
DOIs	https://doi.org/10.1038/s41409-021-01529-x
State	Published - Feb 2022

Bibliographical note

Funding Information:
MH: Research Support/Funding: Takeda Pharmaceutical Company; Consultancy: Incyte Corporation; ADC Therapeutics; Pharmacyclics, Omeros, Kite. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. HA: Consultant and speaker bureau for Incyte, BMS. Research grant from Incyte. IP: Syndax Advisory Board. EvH, WK, and YvO: are employees of Xenikos and own equity in Xenikos. JEL: Research support from Biogen, Incyte, Kamada, and Mesoblast; consulting for Bluebird, Incyte, Jazz, Mesoblast, Omeros, Symbio, Talaris, and X4 Pharmaceuticals; GVHD biomarkers patent and royalties from Viracor.

Funding Information:
The authors wish to acknowledge the support provided by Xenikos and Grant Numbers U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Access

10.1038/s41409-021-01529-x

OpenUrl availability

Full text

Cite this

Meyers, G., Hamadani, M., Martens, M., Ali, H., Choe, H., Dawson, P., Harris, A. C., van Hooren, E., Klaassen, W., Leifer, E., MacMillan, M. L., van Oosterhout, Y., Perez, L., Pusic, I., Vo, P., & Levine, J. E. (2022). Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. Bone marrow transplantation, 57(2), 302-303. https://doi.org/10.1038/s41409-021-01529-x

Meyers, G, Hamadani, M, Martens, M, Ali, H, Choe, H, Dawson, P, Harris, AC, van Hooren, E, Klaassen, W, Leifer, E, MacMillan, ML, van Oosterhout, Y, Perez, L, Pusic, I, Vo, P & Levine, JE 2022, 'Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD', Bone marrow transplantation, vol. 57, no. 2, pp. 302-303. https://doi.org/10.1038/s41409-021-01529-x

@article{13627e205b1f4103b18e7d8a932b7450,

title = "Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD",

author = "Gabrielle Meyers and Mehdi Hamadani and Michael Martens and Haris Ali and Hannah Choe and Peter Dawson and Harris, {Andrew C.} and {van Hooren}, Eric and Willem Klaassen and Eric Leifer and MacMillan, {Margaret L.} and {van Oosterhout}, Ypke and Lia Perez and Iskra Pusic and Phuong Vo and Levine, {John E.}",

note = "Funding Information: MH: Research Support/Funding: Takeda Pharmaceutical Company; Consultancy: Incyte Corporation; ADC Therapeutics; Pharmacyclics, Omeros, Kite. Speaker{\textquoteright}s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. HA: Consultant and speaker bureau for Incyte, BMS. Research grant from Incyte. IP: Syndax Advisory Board. EvH, WK, and YvO: are employees of Xenikos and own equity in Xenikos. JEL: Research support from Biogen, Incyte, Kamada, and Mesoblast; consulting for Bluebird, Incyte, Jazz, Mesoblast, Omeros, Symbio, Talaris, and X4 Pharmaceuticals; GVHD biomarkers patent and royalties from Viracor. Funding Information: The authors wish to acknowledge the support provided by Xenikos and Grant Numbers U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.",

year = "2022",

month = feb,

doi = "10.1038/s41409-021-01529-x",

language = "English (US)",

volume = "57",

pages = "302--303",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

AU - Meyers, Gabrielle

AU - Hamadani, Mehdi

AU - Martens, Michael

AU - Ali, Haris

AU - Choe, Hannah

AU - Dawson, Peter

AU - Harris, Andrew C.

AU - van Hooren, Eric

AU - Klaassen, Willem

AU - Leifer, Eric

AU - MacMillan, Margaret L.

AU - van Oosterhout, Ypke

AU - Perez, Lia

AU - Pusic, Iskra

AU - Vo, Phuong

AU - Levine, John E.

N1 - Funding Information: MH: Research Support/Funding: Takeda Pharmaceutical Company; Consultancy: Incyte Corporation; ADC Therapeutics; Pharmacyclics, Omeros, Kite. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. HA: Consultant and speaker bureau for Incyte, BMS. Research grant from Incyte. IP: Syndax Advisory Board. EvH, WK, and YvO: are employees of Xenikos and own equity in Xenikos. JEL: Research support from Biogen, Incyte, Kamada, and Mesoblast; consulting for Bluebird, Incyte, Jazz, Mesoblast, Omeros, Symbio, Talaris, and X4 Pharmaceuticals; GVHD biomarkers patent and royalties from Viracor. Funding Information: The authors wish to acknowledge the support provided by Xenikos and Grant Numbers U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85119658579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119658579&partnerID=8YFLogxK

U2 - 10.1038/s41409-021-01529-x

DO - 10.1038/s41409-021-01529-x

M3 - Letter

C2 - 34815518

AN - SCOPUS:85119658579

SN - 0268-3369

VL - 57

SP - 302

EP - 303

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 2

ER -

Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this